Elsevier Inc.

SHERPA: Unknown

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Bajorin
    Bajorin
  4. Rosenberg
    Rosenberg
  5. Iyer
    Iyer
  6. Solit
    Solit
  7. Feldman
    Feldman
  8. Morris
    Morris
  9. Slovin
    Slovin
  10. Voss
    Voss

Groups

  1. Genitourinary Oncology Service (384)
  2. Solid Tumor Oncology Division (384)
  3. Department of Medicine (383)
  4. GSK Faculty (92)
  5. Surgery (68)
  6. Survivorship Research (63)
  7. Urology (54)
  8. Hematologic Malignancies, Division of (49)
  9. Human Oncology and Pathogenesis Program (49)
  10. Department of Pathology and Laboratory Medicine (46)
Search Within
  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (245)
  2. Meeting Abstract (120)
  3. Review (7)
  4. Conference Paper (6)
  5. Book Section (3)
  6. Editorial (2)
  7. Guidelines (1)
Groups
  1. Genitourinary Oncology Service (384)
  2. Solid Tumor Oncology Division (384)
  3. Department of Medicine (383)
  4. GSK Faculty (92)
  5. Surgery (68)
  6. Survivorship Research (63)

More Groups

People
  1. Robert Motzer (89)
  2. Howard Scher (72)
  3. Dean Bajorin (50)
  4. Jonathan Rosenberg (39)
  5. David Solit (33)
  6. Gopakumar Iyer (33)

More People

Years
  1. 2025 (9)
  2. 2024 (31)
  3. 2023 (12)
  4. 2022 (18)
  5. 2021 (11)
  6. 2020 (10)

More Years

Publications
  1. European Journal of Cancer (96)
  2. Clinical Genitourinary Cancer (63)
  3. Urologic Oncology: Seminars and Original Investigations (49)
  4. International Journal of Radiation Oncology, Biology, Physics (47)
  5. Seminars in Oncology (41)
  6. Hematology/Oncology Clinics of North America (10)

More Publications

Results (384)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Efficacy and safety of abiraterone acetate (AA) in elderly (75 years) chemo-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Smith, M. R.; Rathkopf, D.; Mulders, P.; Carles, J.; Van Poppel, H.; Li, J.; Kheoh, T.; Griffin, T.; Molina, A.; Ryan, C.
    European Journal of Cancer (2013)

    Fulltext@MSK | Save
  • ARN-509 in men with high risk non-metastatic castration-resistant prostate cancer
    Meeting Abstract

    Smith, M. R.; Antonarakis, E. S.; Ryan, C. J.; Berry, W. R.; Shore, N. D.; Liu, G.; Alumkal, J. J.; Higano, C. S.; Maneval, E. C.; Rathkopf, D. E.
    European Journal of Cancer (2013)

    Fulltext@MSK | Save
  • Evaluation of a composite biomarker panel including circulating tumor cell (CTC) enumeration as a surrogate for survival in metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Scher, H. I.; Heller, G.; Molina, A.; Attard, G.; McCormack, R.; Riisnaes, R.; Kheoh, T.; Fleisher, M.; Buyse, M.; de Bono, J. S.
    European Journal of Cancer (2013)

    Fulltext@MSK | Save
  • Sensitivity analyses for radiographic progression-free survival (rPFS): Results from the phase 3 AFFIRM trial comparing enzalutamide to placebo
    Meeting Abstract

    Scher, H.; Fizazi, K.; Sternberg, C. N.; Armstrong, A.; Bhattacharya, S.; Hirmand, M.; de Bono, J.
    European Journal of Cancer (2013)

    Fulltext@MSK | Save
  • Androgen receptor (AR) and AR-signaling directed therapies in the age of precision medicine
    Meeting Abstract

    Scher, H.
    European Journal of Cancer (2013)

    Fulltext@MSK | Save
  • HER2 tissue expression in NeuACT, a phase 2, randomised, open-label trial of DN24-02 in patients (pts) with surgically resected HER2+ urothelial cancer (UC) at high risk for recurrence
    Meeting Abstract

    Press, M. F.; O'Donnell, P. H.; Plimack, E. R.; Hoffman-Censits, J.; Quinn, D. I.; Sharma, P.; DeVries, T.; Chen, M.; Locker, M.; Bajorin, D. F.
    European Journal of Cancer (2013)

    Fulltext@MSK | Save
  • Long-term safety with sunitinib (SU) in metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Porta, C.; Gore, M. E.; Rini, B. I.; Escudier, B.; Charles, L. P.; Chen, L.; Hariharan, S.; Motzer, R. J.
    European Journal of Cancer (2013)

    Fulltext@MSK | Save
  • A validated prognostic model for predicting overall survival in patients with metastatic chemotherapy naive castrate-resistant prostate cancer
    Meeting Abstract

    Halabi, S.; Lin, C. Y.; Kelly, W. K.; Fizazi, K.; Moul, J. W.; Kaplan, E.; Morris, M. J.; Small, E. J.
    European Journal of Cancer (2013)

    Fulltext@MSK | Save
  • Treatment sequencing following first-line sunitinib in patients (pts) with advanced renal cell carcinoma (RCC)
    Meeting Abstract

    Gore, M. E.; Hutson, T. E.; Lin, X.; Korytowsky, B.; Lechuga, M. J.; Matczak, E.; Figlin, R. A.; Bukowski, R.; Motzer, R. J.
    European Journal of Cancer (2013)

    Fulltext@MSK | Save
  • CA184-043: A randomized, multicenter, double-blind phase 3 trial comparing overall survival (OS) in patients (pts) with post-docetaxel castration-resistant prostate cancer (CRPC) and bone metastases treated with ipilimumab (ipi) vs placebo (pbo), each following single-dose radiotherapy (RT)
    Meeting Abstract

    Gerritsen, W. R.; Kwon, E. D.; Fizazi, K.; Bossi, A.; Van den Eertwegh, A.; Logothetis, C.; Scher, H. I.; Beer, T. M.; McHenry, M. B.; Gagnier, P.; more...
    European Journal of Cancer (2013)

    Fulltext@MSK | Save